comprehensive -WSS

comprehensive

author：knowledge 2025-09-30 21:58:21 - browse：1478

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： The Pandemic Treaty must support building strong health systems

focus

leisure time

WSS

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Readout LOUD podcast: ESMO highlights & Roivant's big deal

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Bill would allow buprenorphine prescription for addiction via telehealth

Coloradans with cystic fibrosis could lose access to Trikafta

Kidney transplant patients stopped immunosuppressants in trial

focus

comprehensive

entertainment

New air purifier tech could be key to improving indoor air quality

Key Senate panel to consider PBM, drug pricing reform package

Malaria cases in Florida and Texas: Here’s what you need to know

Intellia reports positive results for its CRISPR

FDA approval of Sarepta Duchenne genetic therapy gives me hope

After Sarepta trial failure, Duchenne families brace for more debate

The cancer drug shortage isn’t new — and neither are the solutions

See how much Covid

Medical records are filled with copy

What is microchimerism and how does it affect maternal health?

Wikipedia

Ultragenyx gene therapy for rare liver ailment succeeds in late

Humans aren't the only ones with an imagination. Rats have it too

Bill would allow buprenorphine prescription for addiction via telehealth

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

HIV drugs protect against transmission, even in unprotected sex

The Pandemic Treaty must support building strong health systems

entertainment

focus

leisure time

hotspot